JPWO2021041773A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021041773A5 JPWO2021041773A5 JP2022513569A JP2022513569A JPWO2021041773A5 JP WO2021041773 A5 JPWO2021041773 A5 JP WO2021041773A5 JP 2022513569 A JP2022513569 A JP 2022513569A JP 2022513569 A JP2022513569 A JP 2022513569A JP WO2021041773 A5 JPWO2021041773 A5 JP WO2021041773A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- medicament
- ted
- inhibitor
- igf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101359A JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962892849P | 2019-08-28 | 2019-08-28 | |
| US62/892,849 | 2019-08-28 | ||
| PCT/US2020/048350 WO2021041773A1 (en) | 2019-08-28 | 2020-08-28 | Methods for the treatment of thyroid eye disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101359A Division JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545835A JP2022545835A (ja) | 2022-10-31 |
| JPWO2021041773A5 true JPWO2021041773A5 (https=) | 2023-09-05 |
| JP2022545835A5 JP2022545835A5 (https=) | 2023-09-05 |
Family
ID=74686009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513569A Pending JP2022545835A (ja) | 2019-08-28 | 2020-08-28 | 甲状腺眼症の治療方法 |
| JP2025101359A Pending JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101359A Pending JP2025146837A (ja) | 2019-08-28 | 2025-06-17 | 甲状腺眼症の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210253719A1 (https=) |
| EP (1) | EP4021500A4 (https=) |
| JP (2) | JP2022545835A (https=) |
| CN (1) | CN115175701A (https=) |
| AU (1) | AU2020337958A1 (https=) |
| BR (1) | BR112022003663A2 (https=) |
| CA (1) | CA3152740A1 (https=) |
| CO (1) | CO2022003582A2 (https=) |
| WO (1) | WO2021041773A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| WO2019118928A1 (en) | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| WO2019173352A1 (en) | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| BR112022003663A2 (pt) | 2019-08-28 | 2022-05-24 | Horizon Therapeutics Ireland Dac | Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted) |
| CN113512116B (zh) * | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
| CN119792512A (zh) * | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| CN113143928A (zh) * | 2021-04-02 | 2021-07-23 | 苏州普乐康医药科技有限公司 | 一种osi-906的应用 |
| TW202320850A (zh) * | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
| IL316340A (en) * | 2022-05-26 | 2024-12-01 | Horizon Therapeutics Ireland Dac | Methods and preparations for treating thyroid eye disease |
| UY40458A (es) * | 2022-09-30 | 2024-04-15 | Horizon Therapeutics Ireland Dac | Métodos para el tratamiento de la enfermedad ocular tiroidea inactiva |
| WO2025014774A1 (en) * | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
| TW202517640A (zh) * | 2023-07-18 | 2025-05-01 | 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 | 用於治療疾病之ｉｇｆ－１ｒ的雜環抑制劑 |
| WO2025051229A1 (zh) | 2023-09-08 | 2025-03-13 | 北京拓界生物医药科技有限公司 | Igf-1r及tshr结合蛋白及其医药用途 |
| WO2025155888A1 (en) * | 2024-01-19 | 2025-07-24 | Sling Therapeutics, Inc. | Use of inhibitors of insulin-like growth factor receptor-1 for ocular-associated disorders |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2373192A (en) | 1943-03-13 | 1945-04-10 | Walter M Lauer | Antioxidants |
| US4567253A (en) | 1984-02-03 | 1986-01-28 | Tony Durst | 2-Substituted derivatives of podophyllotoxin and etoposide |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| US8178304B2 (en) | 2000-10-06 | 2012-05-15 | Smith Terry J | Diagnostic methods relating to Graves' disease and other autoimmune disorders |
| US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| TWI378934B (en) | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| WO2006080450A1 (ja) | 2005-01-27 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Igf-1r阻害剤 |
| ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| US7612178B2 (en) | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| HRP20140688T1 (hr) | 2006-07-07 | 2014-10-24 | Bristol-Myers Squibb Company | Inhibitori piroltriazin kinaze |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| PL2077830T3 (pl) | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| US20100216779A1 (en) | 2007-06-01 | 2010-08-26 | Glaxosmithkline Llc | Imidazopyridine Kinase Inhibitors |
| US7981903B2 (en) | 2007-08-08 | 2011-07-19 | Glaxosmithkline Llc | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer |
| CA2697612A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| WO2011158931A1 (ja) | 2010-06-17 | 2011-12-22 | 協和発酵キリン株式会社 | インダゾール誘導体の有用な塩 |
| CN103108873A (zh) | 2010-07-16 | 2013-05-15 | 皮拉马尔企业有限公司 | 作为激酶抑制剂的取代的咪唑并喹啉衍生物 |
| UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
| US8546443B2 (en) | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| AR089776A1 (es) | 2012-01-23 | 2014-09-17 | Boehringer Ingelheim Int | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| WO2016064716A1 (en) | 2014-10-20 | 2016-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination therapy of tshr antagonist and igfr inhibitor |
| EP3294742B1 (en) | 2015-05-13 | 2020-01-08 | Boehringer Ingelheim International GmbH | New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors. |
| US11208489B2 (en) | 2018-01-24 | 2021-12-28 | Horizon Therapeutics Ireland Dac | Methods for the treatment of thyroid eye disease |
| US20210284741A1 (en) * | 2018-01-24 | 2021-09-16 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| US10457740B1 (en) * | 2018-01-29 | 2019-10-29 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer using P2RX2 inhibitors |
| WO2019173352A1 (en) | 2018-03-05 | 2019-09-12 | Hznp Limited | Methods for the treatment of thyroid eye disease |
| BR112022003663A2 (pt) | 2019-08-28 | 2022-05-24 | Horizon Therapeutics Ireland Dac | Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted) |
-
2020
- 2020-08-28 BR BR112022003663A patent/BR112022003663A2/pt unknown
- 2020-08-28 EP EP20858844.2A patent/EP4021500A4/en active Pending
- 2020-08-28 JP JP2022513569A patent/JP2022545835A/ja active Pending
- 2020-08-28 CA CA3152740A patent/CA3152740A1/en active Pending
- 2020-08-28 WO PCT/US2020/048350 patent/WO2021041773A1/en not_active Ceased
- 2020-08-28 AU AU2020337958A patent/AU2020337958A1/en active Pending
- 2020-08-28 CN CN202080074509.4A patent/CN115175701A/zh active Pending
-
2021
- 2021-03-03 US US17/191,651 patent/US20210253719A1/en not_active Abandoned
-
2022
- 2022-03-10 US US17/654,318 patent/US12600787B2/en active Active
- 2022-03-25 CO CONC2022/0003582A patent/CO2022003582A2/es unknown
-
2025
- 2025-06-17 JP JP2025101359A patent/JP2025146837A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021041773A5 (https=) | ||
| CN1191859C (zh) | 用于治疗癌症的泰素帝和重组人源化her2单克隆抗体的组合 | |
| EP1616572B1 (en) | Chimeric anti-CD20 antibody, rituxan, for use in the treatment of chronic lymphocytic leukemia | |
| Gamalero et al. | Evidence-based treatment for uveitis | |
| Milligan et al. | A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. | |
| JP2022177142A5 (https=) | ||
| CN111032082B (zh) | Her2阳性癌症的治疗 | |
| JP5212849B2 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬 | |
| CN1466464A (zh) | 癌症治疗药 | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| CA2944811C (en) | Combination therapy for the treatment of autoimmune diseases | |
| JP2021526138A5 (https=) | ||
| WO2008031835A2 (en) | Method of treating autoimmune diseases using vegf-pathway inhibitors | |
| CA2465471C (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| JP2002501028A (ja) | スピカマイシンまたはその誘導体を用いた疼痛の減少法または予防法 | |
| Bruckner et al. | 295 Collagen 7 (C7) protein replacement therapy (PTR-01) durably reduces wound size and symptoms in patients with recessive dystrophic epidermolysis bullosa (RDEB) | |
| JPWO2021076514A5 (https=) | ||
| WO2011156900A2 (en) | Compounds, compositions and methods for treatment of multiple sclerosis | |
| RU2832833C1 (ru) | Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком | |
| JPWO2021048280A5 (https=) | ||
| Tachiki et al. | 292 Is it safe to discontinue immunotherapy after a response in Merkel cell carcinoma? | |
| JP2025537848A (ja) | 多発性硬化症の治療方法 | |
| Akkus et al. | Recent treatment guidelines and approach toward autoimmune encephalitis | |
| WO2024231875A1 (en) | Hpk1 inhibitor for use in the treatment of cancer | |
| WO2026024933A1 (en) | Cdk inhibitors and their use as pharmaceuticals |